利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.022 秒)

    Controlled-release garlic formulations
    1.
    发明授权
    Controlled-release garlic formulations 失效
    控释大蒜制剂

    公开(公告)号：US06270803B1

    公开(公告)日：2001-08-07

    申请号：US09392754

    申请日：1998-10-07

    申请人： Yoav Blatt ,  David Cohen ,  Eugene Kimmelman ,  Oded Friedman ,  Avner Rotman

    发明人： Yoav Blatt ,  David Cohen ,  Eugene Kimmelman ,  Oded Friedman ,  Avner Rotman

    IPC分类号： A61K914

    CPC分类号： A61K9/5073 ,  A61K9/2081 ,  A61K9/5042 ,  A61K9/5047 ,  A61K36/8962 ,  A61K2300/00

    摘要： There are provided orally-administrable formulations for the controlled release of granulated garlic, comprising particles of granulated garlic coated with a film comprising a mixture of at least one water soluble polymer and at least one water insoluble polymer, said at least one water soluble polymer and at least one water insoluble polymer being present in a ratio that produces a substantially zero order linear release pattern of at least one active ingredient. Preferably, the formulations are characterized in that the total in vitro dissolution time of said formulations required for release of 75% of the Allicin available from said formulations based upon the total amount of alliin initially present in said formulations is between about 4 and about 12 hours, as determined by U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for preparing the formulations of the invention is also disclosed.

    摘要翻译： 提供了用于受控释放造粒大蒜的口服给药制剂，其包括用包含至少一种水溶性聚合物和至少一种水不溶性聚合物的混合物的膜的粒状大蒜颗粒，所述至少一种水溶性聚合物和 至少一种水不溶性聚合物以一定比例存在，其产生至少一种活性成分的基本零级线性释放模式。 优选地，制剂的特征在于，基于最初存在于所述制剂中的蒜素的总量，从所述制剂释放75％的大蒜素所需的所述制剂的总体外溶出时间为约4至约12小时 ，由USP确定 XXIII桨法以150rpm的桨叶速度，使用模拟肠液，不含肠液中通常存在的消化酶，含有0.1％w / w十二烷基硫酸钠（SDS），pH 6.8，温度为37℃。 还公开了制备本发明制剂的方法。

    Microencapsulated and controlled-release herbal formulations
    2.
    发明授权
    Microencapsulated and controlled-release herbal formulations 失效
    微囊化和控制释放草药制剂

    公开(公告)号：US06340478B1

    公开(公告)日：2002-01-22

    申请号：US09327752

    申请日：1999-06-07

    申请人： Yoav Blatt ,  Eugene Kimmelman ,  David Cohen ,  Avner Rotman

    发明人： Yoav Blatt ,  Eugene Kimmelman ,  David Cohen ,  Avner Rotman

    IPC分类号： A61K3578

    CPC分类号： A61K9/5047 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2081

    摘要： There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated herb, comprising a granulated herb and at least one carrier, adjuvant or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 150 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, containing 0.1% w/w sodium dodecyl sulfate (SDS), at pH 6.8, and a temperature of 37° C. A process for the preparation of such formulation is also provided.

    摘要翻译： 提供了用于控制释放或稳定储存颗粒状药物的口服制剂，其包含颗粒状药草和至少一种载体，佐剂或赋形剂。 优选地，所述制剂的特征在于，释放所述制剂中可获得的75％活性成分所需的所述制剂的总体外溶出时间为约4至约18小时，如U.S.P。 XXIII桨法以150rpm的桨叶速度，使用模拟肠液，不含肠液中通常存在的消化酶，含有0.1％w / w十二烷基硫酸钠（SDS），pH 6.8，温度为37℃。 还提供了制备这种制剂的方法。

    Controlled release chromium picolinate
    3.
    发明授权
    Controlled release chromium picolinate 失效
    受控释放的吡啶甲酸铬

    公开(公告)号：US6156347A

    公开(公告)日：2000-12-05

    申请号：US10165

    申请日：1998-01-21

    申请人： Yoav Blatt ,  Oded Friedman ,  Eugene Kimelman ,  Avner Rotman

    发明人： Yoav Blatt ,  Oded Friedman ,  Eugene Kimelman ,  Avner Rotman

    IPC分类号： A61K9/22 ,  A61K9/50 ,  A61K31/4402 ,  A61K31/555 ,  A61K33/24

    CPC分类号： A61K31/555 ,  A61K31/4402 ,  A61K33/24 ,  A61K9/5078

    摘要： The present invention relates to controlled/extended release oral dosage forms of chromium picolinate. Chromium picolinate is a common and effective biologically active form of chromium. As such, it has beneficial nutritional and therapeutic effects including improved insulin metabolism and lipid lowering activity.The controlled dosage form of the present invention can be provided in various ways, including matrix formulations such as matrix tablets or multiparticulate formulations like micro capsules or coated pellets put into hard gelatin capsules. This provides effective drug delivery for extended periods of time, at relatively stable, optimal plasma peak values, with minimal undesirable side effects.The invention provides effective controlled/extended release oral dosage formulations of chromium picolinate and processes for their preparation.

    摘要翻译： 本发明涉及吡啶甲酸铬的受控/延长释放的口服剂型。 吡啶甲酸铬是一种常见且有效的生物活性形式的铬。 因此，它具有有益的营养和治疗效果，包括改善的胰岛素代谢和降脂活性。 本发明的受控剂型可以以各种方式提供，包括基质制剂如基质片剂或多颗粒制剂如微胶囊或放入硬明胶胶囊中的包衣丸剂。 这提供了在相对稳定的最佳血浆峰值下延长的时间段的有效药物递送，具有最小的不希望的副作用。 本发明提供了有效的控制/延长释放的吡啶甲酸铬的口服剂量制剂及其制备方法。

    Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants
    4.
    发明授权
    Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants 有权
    来自大豆和其他植物的富集部分的异黄酮的微胶囊化和控释制剂

    公开(公告)号：US06890561B1

    公开(公告)日：2005-05-10

    申请号：US10069388

    申请日：2000-08-15

    申请人： Yoav Blatt ,  Oded Arad ,  Eugene Kimelman ,  David Cohen ,  Rika Pinto ,  Avner Rotman

    发明人： Yoav Blatt ,  Oded Arad ,  Eugene Kimelman ,  David Cohen ,  Rika Pinto ,  Avner Rotman

    IPC分类号： A61K9/16 ,  A61K9/26 ,  A61K9/50 ,  A61K9/52 ,  A61K9/54 ,  A61K31/352 ,  A61K9/14 ,  A61K9/20 ,  A61K9/22 ,  A61K9/48

    CPC分类号： A61K9/1652 ,  A61K9/1635 ,  A61K9/5047 ,  A61K31/352

    摘要： There is provided an orally-administrable formulation for the controlled release or stable storage of a granulated isoflavone-enriched fraction or mixture of such fractions, comprising at least one granulated isoflavone-enriched fraction and at least one carrier, diluent or excipient therefor. Preferably, the formulation is characterized in that the total in vitro dissolution time of said formulation required for release of 75% of the active ingredients available from the formulation is between about 4 and about 18 hours, as determined by the U.S.P. XXIII paddle method at a paddle speed of 75 rpm, using simulated intestinal fluid without the digestive enzymes normally found in intestinal fluid, at pH 6.8, and a temperature of 37° C. A process for the preparation of such a formulation is also provided.

    摘要翻译： 提供了一种可口服给药的制剂，其用于控制​​释放或稳定地储存富含粒状异黄酮的级分或这些级分的混合物，其包含至少一种颗粒状异黄酮富集部分和至少一种载体，稀释剂或赋形剂。 优选地，所述制剂的特征在于，释放所述制剂中可获得的75％活性成分所需的所述制剂的总体外溶出时间为约4至约18小时，如U.S.P。 XXIII桨法以桨叶速度为75rpm，使用模拟肠液，没有通常在肠液中发现的消化酶，pH 6.8，温度为37℃。还提供了制备这种制剂的方法。

    Heat stabilized flavoring agents coated with hydrogenated castor oil
    5.
    发明授权
    Heat stabilized flavoring agents coated with hydrogenated castor oil 失效
    用氢化蓖麻油涂覆的耐热稳定剂

    公开(公告)号：US5098725A

    公开(公告)日：1992-03-24

    申请号：US501079

    申请日：1990-03-29

    申请人： Avner Rotman ,  Yoav Blatt

    发明人： Avner Rotman ,  Yoav Blatt

    IPC分类号： A21D2/00 ,  A21D2/02 ,  A23L1/00 ,  A23L1/22 ,  A23L1/236

    CPC分类号： A21D2/00 ,  A21D2/02 ,  A23L27/32 ,  A23L27/72 ,  A23P10/35

    摘要： Very small particles of flavoring materials which are labile when subjected to both heat and an aqueous medium are coated with a coating material containing hydrogenated castor oil and having a melting point of from about 80.degree. to about 100.degree. C. The coating layer remains stable during the first minutes of the baking process, when the concentration of water in the dough or batter is relatively high. After several minutes, when most of the water in the dough or batter has evaporated and the temperature increases to about 100.degree. C., the coating layer or layers melt away. Within a few minutes thereafter, the active ingredient is exposed within the product. Alternatively, a leavening agent may be used wihtin the capsule which will release a gas at the predetermined temperature and cause rupture of the microencapsulation.

    Synergistic compositions and methods
    7.
    发明授权
    Synergistic compositions and methods 有权
    协同作曲和方法

    公开(公告)号：US08460718B2

    公开(公告)日：2013-06-11

    申请号：US13081643

    申请日：2011-04-07

    申请人： Morris Zelkha ,  Yoav Blatt ,  Yossi Levy ,  Yoav Sharoni

    发明人： Morris Zelkha ,  Yoav Blatt ,  Yossi Levy ,  Yoav Sharoni

    IPC分类号： A01N65/00

    CPC分类号： A61K31/01 ,  A61K31/07 ,  A61K31/122 ,  A61K31/56 ,  A61K31/575 ,  A61K2300/00

    摘要： Pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a synergistic combination of lycopene and at least one phytosterol wherein the ratio of said lycopene to said phytosterol in said pharmaceutical composition is a maximum of about 5:1 and wherein said composition produces a synergistic inhibition of cell growth are disclosed.

    摘要翻译： 用于口服给药的药物组合物包含治疗有效量的番茄红素和至少一种植物甾醇的协同组合，其中所述药物组合物中所述番茄红素与所述植物甾醇的比例最大为约5:1，并且其中所述组合物产生协同抑制 的细胞生长。